High-throughput screening for kinase inhibitors

ChemBioChem

Volumn 6, Issue 3, 2005, Pages 481-490

  Von Ahsen, Oliver ^a   Bömer, Ulf ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Assay development; Drug discovery; High throughput screening; Inhibitors; Kinases

Indexed keywords

FASUDIL; G PROTEIN COUPLED RECEPTOR; GEFITINIB; IMATINIB; PROTEIN KINASE INHIBITOR; RAPAMYCIN; RHO KINASE; TARGET OF RAPAMYCIN KINASE; PROTEIN KINASE;

CHEMOLUMINESCENCE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME SPECIFICITY; FLUORESCENCE POLARIZATION IMMUNOASSAY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN GENOME; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCINTILLATION; DRUG SCREENING; METABOLISM; METHODOLOGY;

DRUG EVALUATION, PRECLINICAL; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SUBSTRATE SPECIFICITY;

EID: 20444432725     PISSN: 14394227     EISSN: None     Source Type: Journal    
DOI: 10.1002/cbic.200400211     Document Type: Review

References (53)

1. P. Cohen, Nat. Rev. Drug Discovery 2002, 1, 309-315.
2. G. Manning, D. B. White, R. Martinez, T. Hunter, S. Sudarsanam, Science 2002, 298, 1912-1934.
3. W. P. Walters, M. Namchuk, Nat. Rev. Drug Discovery 2003, 2, 259-266.
4. L. K. Minor, Curr. Opin. Drug Discovery Dev. 2003, 6, 760-765.
5. a) A. J. Walhout, G. F. Temple, M. A. Brasch, J. L. Hartley, M. A. Lorson, S. van den Heuvel, M. Vidal, Methods Enzymol. 2000, 328, 575-592;
6. b) H. T. Ding, H. Ren, Q. Chen, G. Fang, L. F. Li, R. Li, Z. Wang, X. Y. Jia, Y. H. Liang, M. H. Hu, Y. Li, J. C. Luo, X. C. Gu, X. D. Su, M. Luo, S. Y. Lu, Acta Crystallogr. Sect. D Biol. Crystallogr. 2002, 58, 2102-2108.
7. R. A. Copeland, Anal. Biochem. 2003, 320, 1-12.
8. C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, Adv. Drug Delivery Rev. 1997, 23, 3-25.
9. K. Y. Horiuchi, P. A. Scherle, J. M. Trzaskos, R. A. Copeland, Biochemistry 1998, 37, 8879-8885.
10. S. K. Buddai, L. Toulokhonova, P. W. Bergum, G. P. Vlasuk, S. Krishnaswamy, J. Biol. Chem. 2002, 277, 26 689-26 698.
11. J. Comley, Drug Discovery World 2003, 91-98.
12. a) J. J. Wu, Methods Mol. Biol. (Towota, NJ, US) 2002, 190, 65-85;
13. b) Y. W. Park, R. T. Cummings, L. Wu, S. Zheng, P. M. Cameron, A. Woods, D. M. Zaller, A. I. Marcy, J. D. Hermes. Anal. Biochem. 1999, 269, 94-104.
14. A. Fowler, D. Swift, E. Longman, A. Acornley, P. Hemsley, D. Murray, J. Unitt, I. Dale, E. Sullivan, M. Coldwell, Anal. Biochem. 2002, 308, 223-231.
15. T. C. Turek-Etienne, M. Lei, J. S. Terracciano, E. F. Langsdorf, R. W. Bryant, R. F. Hart, A. C. Horan, J. Biomol. Screening 2004, 9, 53-61.
16. a) J. R. Beasley, D. A. Dunn, T. L. Walker, S. M. Parlato, J. M. Lehrach, D. S. Auld, Assay Drug Dev. Technol. 2003, 1, 455-459;
17. b) E. M. G. Loomans, A. M. van Doornmalen, J. W. Y. Wat, G. J. R. Zaman, Assay Drug Dev. Technol. 2003, 1, 445-453.
18. Y. Li, R. T. Cummings, B. R. Cunningham, Y. Chen, G. Zhou, Anal. Biochem. 2003, 321, 151-156.
19. J. Dunne, H. Reardon, V. Trinh, E. Li, J. Farinas, Assay Drug Dev. Technol. 2004, 2, 121-129.
20. http://www.mesoscale.com
21. H. Yang, J. K. Leland, D. Yost, R. J. Massey, Biotechnology 1994, 12, 193-194;
22. b) R. H. Schweitzer, L. Abriola, Methods Mol. Biol. (Towota, NJ, US) 2002, 190, 87-106.
23. http://www.piercenet.com
24. K. Kupcho, R. Somberg, B. Bulleit, S. A. Goueli, Anal. Biochem. 2003, 317, 210-217.
25. R. M. Eglen, Assay Drug Dev. Technol. 2002, 1, 97-104.
26. http://www.cambrex.com
27. a) St. M. Rodems, B. D. Hamman, C. Lin, J. Zhao, S. Shah, D. Heidary, L. Makings, J. H. Stack, B. A. Pollok, Assay Drug Dev. Technol. 2002, 1, 9-19;
28. b) http://www.invitrogen.com
29. P. B. Taylor, F. P. Stewart, D. J. Dunnington, S. T. Quinn, C. K. Schulz, K. S. Vaidya, E. Kurali, T. R. Lane, W. C. Xiong, T. P. Sherill, J. S. Snider, N. D. Terpstra, R. P. Hertzberg, J. Biomol. Screening 2000, 5, 213-225.
30. J. H. Zhang, T. D. Y. Chung, K. R. Oldenburg, J. Biomol. Screening 1999, 4, 67-73.
31. S. J. Teague, A. M. Davis, P. D. Leeson, T. Oprea, Angew. Chem. 1999, 111, 3962-3967;
32. Angew. Chem. Int. Ed. 1999, 38, 3743-3748.
33. G. M. Rishton, Drug Discovery Today 2003, 8, 86-96.
34. S. L. McGovern, E. Caselli, N. Grigoriell, B. K. Shoichet, J. Med. Chem. 2002, 45, 1712-1722.
35. O. Roche, P. Schneider, J. Zuegge, W. Guba, M. Kansy, A. Alanine, K. Bleicher, F. Danel, E. M. Gutknecht, M. Rogers-Evans, W. Neidhart, H. Stalder, M. Dillon, E. Sjogren, N. Fotouhi, P. Gillespie, R. Goodnow, W. Harris, P. Jones, M. Taniguchi, S. Tsujii, W. von der Saal, G. Zimmermann, G. Schneider, J. Med. Chem. 2002, 45, 137-142.
36. T. K. Garyantes, Drug Discovery Today 2002, 7, 489-490.
37. a) A. Alanine, M. Nettekoven, E. Roberts, A. W. Thomas, Comb. Chem. High Throughput Screening 2003, 6, 51-66;
38. b) K. H. Bleicher, H.-J. Böhm, K. Müller, A. I. Alanine, Nat. Rev. Drug Discovery 2003, 2, 369-378;
39. c) R. Deprez-Poulain, B. Deprez, Curr. Topics Med. Chem. 2004, 4, 569-580.
40. O. Prien, ChemBioChem 2005, 6, 500-505.
41. M. J. Valler, D. Green, Drug Discovery Today, 2000, 5, 286-293.
42. J. J. Devlin, A. Liang, L. Trinh, M. A. Polokoff, D. Senator, W. Zheng, J. Kondracki, P. J. Kretschmer, J. Morser, S. E. Lipson, R. Spann, J. A. Loughlin, K. V. Dunn, M. M. Morrissey, Drug Dev. Res. 1996, 35, 80-85.
43. a) M. Snider, J. Biomol. Screening 1998, 3, 169-170;
44. b) T. D. Y Chung, J. Biomol. Screening 1998, 3, 171-173.
45. M. Hann, B. Hudson, X. Lewell, R. Lifely, L. Miller, N. Ramsden, J. Chem. Inf. Comput. Sci. 1999, 39, 897-902.
46. S. Cohen, R. F. Trinka, Methods Mol. Biol. (Towota, NJ, US) 2002, 190, 213-228.
47. K. C. Menke, Methods Mol. Biol. (Towota, NJ, US) 2002, 190, 195-212.
48. a) M. A. Sills, J. Biomol. Screening 1997, 2, 137-138;
49. b) K. R. Oldenburg, J. Biomol. Screening 1999, 4, 53-56;
50. c) M. J. Wildey, C. A. Homon, B. Hutchins, J. Biomol. Screening 1999, 4, 57-60.
51. M. E. M. Noble, J. A. Endicott, L. N. Johnson, Science 2004, 303, 1800-1805.
52. a) S. P. Davies, H. Reddy, M. Caivano, P. Cohen, Biochem. J. 2000, 3S1, 95-105;
53. b) J. Bain, H. McLauchlan, M. Elliot, P. Cohen, Biochem. J. 2003, 371, 199-204.